Is Gala GLP-1 legit and worth it?
Gala GLP-1 is a real GLP-1 telehealth provider; we read its site and scored it 3.5/5 in our independent review (Competitive but Mixed). Biggest plus: Competitive pricing $199-$299/mo. Watch-out: No lab testing or dietitian.
Scorecard: strongest in Access (4.7/5) and Reputation (4.1/5); weakest in Authenticity (2.7/5) and Patient Protection (3.4/5).
Platform: Clinician network: OpenLoop Healthcare Partners, PC — a disclosed vendor relationship. Recorded from the provider’s own disclosures, checked September 7, 2026.
Medications
Compounded Semaglutide, Compounded Tirzepatide (as listed on its site, 7 April 2026)
Monthly Cost
$199-$299/mo (as listed on its site, 7 April 2026)
Speed to Start
Fast
Prices and medications in this review are as listed on Gala GLP-1’s site on 7 April 2026, unless a line is marked otherwise, and have not been re-checked since. Note added 13 October 2026.
Corrected 14 October 2026: this review previously gave a Better Business Bureau rating or listing status. We kept no record of where it came from, so it has been removed. Trustpilot figures in this review are as recorded in April 2026 and have not been re-checked.
Est. 2023
About Gala GLP-1
Gala GLP-1 is a 2023-founded telehealth provider offering compounded semaglutide and tirzepatide at prices between $199 and $299 per month. The company entered a crowded market but has built a modest following with competitive pricing and a straightforward enrollment process. Gala positions itself as an accessible option for patients who want GLP-1 therapy without the premium pricing charged by larger platforms.
The pricing structure is one of Gala’s more attractive features. With a 9 ceiling on monthly costs, the platform avoids the sticker shock that some competitors create with tiered plans reaching ,000 or more. Both semaglutide and tirzepatide are available as compounded formulations, giving patients the option to try either GLP-1 receptor agonist pathway. The onboarding process includes a medical intake and asynchronous provider review, which is standard for the category.
On Trustpilot, Gala GLP-1 holds a 4.4-star rating from 975+ reviews, a respectable score that suggests generally positive patient experiences. The review count is growing, and the rating has remained stable as volume increases, which is a positive signal. Common praise points include medication effectiveness and reasonable pricing. Complaints tend to center on shipping delays and communication gaps during the fulfillment process.
The F grade appears driven by complaint volume relative to the company’s size and unresolved disputes. Support is moderate, with Gala offering some level of ongoing patient communication but falling short of the comprehensive check-in protocols that top-tier providers maintain.
Gala GLP-1 is a growing provider still establishing its operational maturity. The fundamentals are reasonable: competitive pricing, both major GLP-1 compounds available, and solid Trustpilot feedback. The question is whether the company can scale its support infrastructure to match its patient growth. For now, it occupies a middle position in our rankings, neither a standout nor a concern, but a viable option for price-sensitive patients willing to accept some operational rough edges.
At a Glance
Medications Offered
Compounded Semaglutide, Compounded Tirzepatide (as listed on its site, 7 April 2026)
Compounded
Cost & Insurance
- Monthly: $199-$299/mo (as listed on its site, 7 April 2026)
- 6-month estimate: $1,194-$1,794 (as listed on its site, 7 April 2026)
- Insurance: No
- Self-pay: Yes
Clinical Features
- Lab testing: No
- Dietitian access: No
- Pharmacies named: Third-party partner pharmacy handles prescribing/dispensing/delivery; specific pharmacy not named
Delivery & Access
- Format: Subcutaneous
- Nationwide telehealth: Yes
- Speed: Fast
- Spanish-speaking providers: Not stated Corrected 13 October 2026: this line said “Not available”, but our research had recorded it as unknown.
Start your GLP-1 weight loss journey with Gala GLP-1 today
Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that should only be used under the supervision of a licensed healthcare provider. Individual results may vary.
Editorial Independence: GLP-1.Reviews maintains full editorial independence. We read providers’ own pages and public records and publish what we find, with the date we checked.
Corrected 13 October 2026: this review showed a “Verified Provider” badge and said our scores were “based on verified data and standardized criteria”. Neither described a check we had done, so both have been removed.
What the Gala GLP-1 Intake Looks Like
We walked through the Gala GLP-1 intake ourselves, from the opening goal question through a detailed 42-screen medical history, a trust slide showing a LegitScript-certified badge (claimed; not independently verified), and finally a three-plan Stripe-powered checkout. The safety screens are notably thorough and Gala is one of the few platforms we’ve audited that surfaces a LegitScript certification badge in the flow (claimed; not independently verified).
Wide and specific safety net. Eating disorder, suicidal OR homicidal thoughts, cancer with a 5-year remission rule, pancreatitis, warfarin, QT prolongation, Stage 3A+ kidney disease, and a combined thyroid cyst/nodule/cancer/MTC/MEN-2 screen. A LegitScript certification badge appears in the flow (claimed; not independently verified).
Moderate. 42 screens is longer than the category median, but the pace is fast and the default 3-month plan lands at $199/mo after a $300 discount. Explicit auto-renewal consent on screen 3 — read the subscription language carefully.
The 9 Stages
Clinical Safety Screens Performed
Gala is one of the few GLP-1 telehealth intakes in our catalog that surfaces a LegitScript Certified badge directly on the “Your personalized plan is almost ready” screen, alongside a HIPAA Compliant badge. LegitScript is a third-party compliance vendor that audits pharmacies and telehealth platforms. LegitScript certification claimed; not independently verified: we have not confirmed Gala’s listing in LegitScript’s register. Even if confirmed, it would not substitute for naming the pharmacy. Gala also prints an explicit disclaimer on the same screen: “Our custom GLP-1 formulations are independently developed and may vary in concentration or ingredients from other branded pens. Gala is not affiliated with Novo Nordisk or Eli Lilly.” That language is more honest than the industry norm.
Gala’s contraindication multi-select includes “Current suicidal/homicidal thoughts” as a single combined option. Suicide risk is rare enough in category intakes; the homicidal ideation pairing is effectively unique in our audit. The gate is broader than the norm, and paired with the eating disorder and alcohol-dependence gates it builds a meaningful mental-health-adjacent safety net without requiring a formal PHQ instrument.
In addition to a generic “are you on any medications” yes/no, Gala specifically asks whether the patient uses warfarin (Coumadin / Jantoven) and whether they have QT prolongation or another heart rhythm disorder. Warfarin interaction is clinically relevant because GLP-1-induced changes in gastric emptying can alter absorption of narrow-therapeutic-index drugs, and QT prolongation matters because of the cardiac side-effect profile of some weight-loss adjuncts. Most intakes defer these to the live visit. Gala surfaces them as structured gates in the written flow.
Final checkout is a clean three-card shelf — 3-month plan at $199/mo (Most Popular, $300 off the $299 monthly, $597 due today), 12-month plan at $179/mo (Best Value), or monthly at $299/mo. The checkout is Stripe-powered with 256-bit SSL encryption and a “full refund if not eligible” guarantee. Worth noting: back on screen 3, Gala requires an explicit auto-renewal subscription consent — the patient acknowledges up front that each month auto-renews unless cancelled, and that first-month charges happen after provider review. Patients should read that consent line carefully rather than checking it on autopilot.
The intake does not use a validated PHQ-2 or PHQ-9 depression instrument (mental health is covered by the suicidal/homicidal and eating disorder gates), does not split personal vs family history into separate questions on MTC or MEN-2 (they’re combined in a single “you or a family member” prompt), and does not include a dedicated opioid or broader substance-use screen beyond alcohol dependence. There is no ID upload and no phone OTP.
Source: GLP-1.Reviews editorial walkthrough on April 13, 2026. We completed every screen of the Gala GLP-1 intake using a representative GLP-1 candidate persona and stopped before submitting any payment information.
Opens galaglp1.com in a new tab. We may earn a commission if you start treatment through this link, at no additional cost to you.
